IP Library › Granted Patent US 12,281,118
Granted Patent B2
US 12,281,118 · App. 17/292,027 · Granted Apr 22, 2025

Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use

Inventors: Huixin Wan (Nantong, CN); Jianfeng Pan (Nantong, CN); Jingui Ma (Nantong, CN); Chuantao Cha (Nantong, CN)
Assignee: SHANGHAI RINGENE BIOPHARMA CO., LTD.
C07D487/04A61K9/0019A61K9/0053A61P35/02C07D471/04C07D519/00C07K16/2827
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,118
App. No.
17/292,027
Granted
Apr 22, 2025
Kind
B2
Abstract

Disclosed are a nitrogen-containing fused heterocyclic SHP2 inhibitor compound, a preparation method, and use. The nitrogen-containing fused heterocyclic SHP2 inhibitor compound is represented by formula I below. The compound has high inhibitory activity for an SHP2 enzyme and tumor cell proliferation, and has good druggability.

Claims (6)

1. A nitrogen-containing fused heterocyclic compound, a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a tautomer thereof, a solvate thereof, a polymorph thereof or a prodrug:

2. A pharmaceutical combination comprising the nitrogen-containing fused heterocyclic compound as defined in claim 1 , a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a tautomer thereof, a solvate thereof, a polymorph thereof or a prodrug thereof, and a PD-1 inhibit or the PD-1 inhibitor is a PD-L1 antibody.

3. A pharmaceutical composition, comprising the nitrogen-containing fused heterocyclic compound as defined in claim 1 , a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a tautomer thereof, a solvate thereof, a polymorph thereof or a prodrug thereof, and a pharmaceutically acceptable carrier.

4. A nitrogen-containing fused heterocyclic compound, a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a tautomer thereof, a solvate thereof, a polymorph thereof or a prodrug:

5. A pharmaceutical composition, comprising the nitrogen-containing fused heterocyclic compound as defined in claim 4 , a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a tautomer thereof, a solvate thereof, a polymorph thereof or a prodrug thereof, and a pharmaceutically acceptable carrier.

6. A pharmaceutical combination comprising the nitrogen-containing fused heterocyclic compound as defined in claim 4 , a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a tautomer thereof, a solvate thereof, a polymorph thereof or a prodrug thereof, and a PD-1 inhibit or the PD-1 inhibitor is a PD-L1 antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2021
From: WAN, HUIXIN; PAN, JIANFENG; MA, JINGUI; CHA, CHUANTAO
To: SHANGHAI RINGENE BIOPHARMA CO., LTD.
Reel/Frame 056165/0379 →
Priority Claims (3)
CN 201811317588.8 · Nov 7, 2018 · national
CN 201811594644.2 · Dec 26, 2018 · national
CN 201910131491.6 · Feb 22, 2019 · national
Continuity (1)
Related Publication 20220127271A1 · Apr 28, 2022
References Cited (38)
US 10093646B2 · Chen · 2018 [cited by applicant]
US 10844079B2 · Zheng et al. · 2020 [cited by applicant]
US 20110237565A1 · Borchardt et al. · 2011 [cited by applicant]
US 20160289238A1 · He et al. · 2016 [cited by applicant]
US 20200407372A1 · Koltun et al. · 2020 [cited by applicant]
US 20210053989A1 · Zou et al. · 2021 [cited by applicant]
AU 2019386036A1 · 2021 [cited by applicant]
CN 102869666A · 2013 [cited by applicant]
CN 107660205A · 2018 [cited by applicant]
CN 110156786A · 2019 [cited by applicant]
CN 110655520A · 2020 [cited by applicant]
CN 111138412A · 2020 [cited by applicant]
CN 111433205A · 2020 [cited by applicant]
JP 2013522222A · 2013 [cited by applicant]
JP 2017503000A · 2017 [cited by applicant]
JP 2018510193A · 2018 [cited by applicant]
WO 2014044025A1 · 2014 [cited by applicant]
WO 2015107493A1 · 2015 [cited by applicant]
WO 2018136265A1 · 2018 [cited by applicant]
WO 2018172984A1 · 2018 [cited by applicant]
WO 2019118909A1 · 2019 [cited by applicant]
WO 2019158019A1 · 2019 [cited by applicant]
WO 2020072656A1 · 2020 [cited by applicant]
WO 2020094018A1 · 2020 [cited by applicant]
WO 2020108590A1 · 2020 [cited by applicant]
Jan. 13, 2020 International Search Report issued in International Patent Application No. PCT/CN2019/116386. [cited by applicant]
Jan. 13, 2020 Written Opinion of the International Searching Authority issued in International Patent Application No. PCT/CN2019/116386. [cited by applicant]
Priority document CN 201811317588.8. [cited by applicant]
Priority document CN 201811594644.2. [cited by applicant]
Priority document CN 201910131491.6. [cited by applicant]
Sep. 9, 2020 First Office Action issued in Chinese Patent Application No. 2019110834093. [cited by applicant]
Apr. 8, 2021 Second Office Action issued in Chinese Patent Application No. 2019110834093. [cited by applicant]
First Office Action issued in Japanese Patent Application No. 2021524993 dated Sep. 21, 2023. [cited by applicant]
Third Chinese Office Action issued in Chinese Application No. 2019110834093, dated Aug. 18, 2021. [cited by applicant]
Extended European Search Report issued in European Patent Application No. 19882124.1 dated Nov. 10, 2022. [cited by applicant]
Office Action issued in Japanese Patent Application No. 2021524993 dated Jul. 2, 2024. [cited by applicant]
First Office Action issued in Korea Patent Application No. KR 10-2021-7017327 dated Nov. 24, 2024. [cited by applicant]
First Office Action issued in European Patent Application No. EP19 882 124.1 dated Dec. 12, 2024. [cited by applicant]